• In the media
  • 'Optimized for the underserved': A new diagno...
Media - published on 17 Jun 2020

'Optimized for the underserved': A new diagnostic test built for low-income settings

In this article for Devex, Catherine Cheney reports on a new, portable diagnostic system for sickle cell disease that could serve as a model for developing testing systems for other diseases in low-resource areas.

In the article, the writer examines how Gazelle, a new testing system for sickle cell disease, could impact testing systems for other health burdens including COVID-19.

Medical diagnostic device company Hemex Health is the US-based creator of Gazelle. It has programmed the diagnostic system to also test for malaria. Gazelle is specifically adapted for use in low- and middle-income countries by being affordable, fast, accurate, and easy to use.

In a discussion of Gazelle's potential application for COVID-19 diagnosis, the article quotes the Foundation's Executive Director Jayasree K. Iyer on the need for fair allocation of any resulting products.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |